Halozyme Therapeutics Temporarily Suspends PEGPH20 Phase 2 Enrollment and Starbucks Slashes their Prices
Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares slumped on Friday, closing down 27.26% on about 20 million shares traded. The company announced that it would temporarily suspend enrollment in an ongoing Phase 2 trial of its PEGPH20 treatment of patients with pancreatic cancer. Halozyme said it would take "precautionary actions" in response to an independent data monitoring committee's suggestion on Thursday. The data monitoring committee "is assessing clinical data that